Inari Medical acquisition could provide Stryker with foothold in peripheral vascular market

Stryker recently announced the completion of the acquisition of Inari Medical, a medical device company specialising in the treatment of venous thromboembolism. Acquiring Inari’s portfolio of venous thrombectomy devices could enable Stryker to gain a foothold in the rapidly growing peripheral vascular device market, says GlobalData.

Inari Medical’s portfolio of devices includes the FlowTriever and ClotTriever systems, which are used to treat pulmonary embolism and deep vein thrombosis, respectively. Both systems utilise a minimally invasive procedure to find and remove these clots from the body. These devices compete with other major cardiovascular device manufacturers, including Boston Scientific, Terumo, and Penumbra.

David Beauchamp, Medical Analyst, GlobalData, comments, “With the rising rates of peripheral artery diseases worldwide, including deep vein thrombosis and complications such as pulmonary embolism, this acquisition is likely to strengthen Stryker’s position in the overall cardiovascular device market.”

According to the GlobalData Medical Intelligence Center, the worldwide thrombectomy device market was worth $2.96 billion in 2024 and is set to register a compound annual growth rate (CAGR) of 5.48 per cent from 2024 to 2034. In the US alone, the thrombectomy market was valued at $1.18 billion and is projected to record a CAGR of 3.38 per cent during the same period. The largest companies in the market include Boston Scientific, Teleflex, and Inari Medical. With the backing of Stryker, it is possible that Inari Medical will see greater success in the thrombectomy device market.

Beauchamp concludes, “As the acquisition of Inari Medical has been finalized, Stryker is now poised to break into the lucrative peripheral vascular device market. Inari’s expertise in thrombectomy devices, combined with Stryker’s existing distribution and logistics network, could result in an improvement in both volume and procedure quality for those suffering from deep vein thrombosis and other clot-related cardiovascular diseases.”

Edits made by EH News Bureau